Please login to the form below

Not currently logged in
Email:
Password:

investment

This page shows the latest investment news and features for those working in and with pharma, biotech and healthcare.

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

While it looks like the end of the road for pegilodecakin in pancreatic cancer, Lilly is still hopeful that its investment in the drug will pay off in other cancer types.

Latest news

More from news
Approximately 8 fully matching, plus 1,670 partially matching documents found.

Latest Intelligence

  • A snapshot of Crescendo Biologics A snapshot of Crescendo Biologics

    With a pipeline promising first-in-class T-cell enhancers, Crescendo has attracted big investments from the pharma industry as its platform attracts global attention.

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    investment and the ease of market access. ... Reic is in step with leaders at EFPIA in saying the EU needs to prioritise investment in science and R&D to maintain the region’s pre-eminence for life sciences.

  • The ‘blueprint’ for MSL success is changing The ‘blueprint’ for MSL success is changing

    Significant and continued investment should be made in MSL development to ensure they are equipped to succeed in their roles. ... They must identify the right talent at the recruitment stage, with desired scientific, technical knowledge and core

  • Rare diseases: redefining medical communications Rare diseases: redefining medical communications

    Interventions for rare diseases have the potential to generate healthy returns on investment, and policy changes to encourage the development of such products are helping to drive the market forward.

  • Building European biotech firms to rival those of the US Building European biotech firms to rival those of the US

    Having said that, there is a lot more private equity money moving into later stage investment in life sciences. ... If that’s happening, then public market investment might not be far behind.

More from intelligence
Approximately 3 fully matching, plus 295 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 94 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 175 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics